Literature DB >> 15681404

Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine.

M Oumouna1, J W Mapletoft, B C Karvonen, L A Babiuk, S van Drunen Littel-van den Hurk.   

Abstract

Commercial killed bovine respiratory syncytial virus (K-BRSV) and formalin-inactivated BRSV (FI-BRSV) tend to induce Th2-type immune responses, which may not be protective and may even be detrimental during subsequent exposure to the virus. In this study we assessed the ability of CpG oligodeoxynucleotides (ODNs) to aid in the generation of effective and protective BRSV-specific immune responses. Mice were immunized subcutaneously with FI-BRSV formulated with CpG ODN, Emulsigen (Em), CpG ODN and Em, or non-CpG ODN and Em. Two additional groups were immunized with K-BRSV or K-BRSV and CpG ODN. After two vaccinations, the mice were challenged with BRSV. FI-BRSV induced Th2-biased immune responses characterized by production of serum immunoglobulin G1 (IgG1) and IgE, as well as interleukin-4 (IL-4), by in vitro-restimulated splenocytes. Formulation of FI-BRSV with CpG ODN, but not with non-CpG ODN, enhanced serum IgG2a and IFN-gamma production by splenocytes, whereas serum IgE was reduced. Although the immune response induced by K-BRSV was not as strongly Th2 biased, the addition of CpG ODN to this commercial vaccine also resulted in a more Th1-type response. Furthermore, the addition of CpG ODN to the BRSV vaccine formulations resulted in enhanced neutralizing antibody responses. Significant production of IL-5, eotaxin, and eosinophilia was observed in the lungs of FI-BRSV- and K-BRSV-immunized mice. However, IL-5 and eotaxin levels, as well as the number of eosinophils, were decreased in the mice vaccinated with the CpG ODN-formulated vaccines. Finally, when formulated with CpG ODN, both FI-BRSV and K-BRSV significantly reduced virus production after challenge with BRSV.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681404      PMCID: PMC546558          DOI: 10.1128/JVI.79.4.2024-2032.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  The role of CpG motifs in innate immunity.

Authors:  A M Krieg
Journal:  Curr Opin Immunol       Date:  2000-02       Impact factor: 7.486

2.  Mechanism and function of a newly identified CpG DNA motif in human primary B cells.

Authors:  G Hartmann; A M Krieg
Journal:  J Immunol       Date:  2000-01-15       Impact factor: 5.422

3.  Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.

Authors:  P J Openshaw; S L Clarke; F M Record
Journal:  Int Immunol       Date:  1992-04       Impact factor: 4.823

Review 4.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

5.  Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Authors:  G Hartmann; R D Weeratna; Z K Ballas; P Payette; S Blackwell; I Suparto; W L Rasmussen; M Waldschmidt; D Sajuthi; R H Purcell; H L Davis; A M Krieg
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

Review 6.  Interferon-gamma: a review.

Authors:  J N Ijzermans; R L Marquet
Journal:  Immunobiology       Date:  1989-10       Impact factor: 3.144

7.  Bovine respiratory syncytial virus-specific IgE is associated with interleukin-2 and -4, and interferon-gamma expression in pulmonary lymph of experimentally infected calves.

Authors:  L J Gershwin; R A Gunther; M L Anderson; A R Woolums; K McArthur-Vaughan; K E Randel; G A Boyle; K E Friebertshauser; P S McInturff
Journal:  Am J Vet Res       Date:  2000-03       Impact factor: 1.156

8.  Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.

Authors:  M Connors; P L Collins; C Y Firestone; A V Sotnikov; A Waitze; A R Davis; P P Hung; R M Chanock; B R Murphy
Journal:  Vaccine       Date:  1992       Impact factor: 3.641

9.  Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus.

Authors:  B S Graham; G S Henderson; Y W Tang; X Lu; K M Neuzil; D G Colley
Journal:  J Immunol       Date:  1993-08-15       Impact factor: 5.422

10.  Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.

Authors:  M Connors; A B Kulkarni; C Y Firestone; K L Holmes; H C Morse; A V Sotnikov; B R Murphy
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more
  12 in total

1.  The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Yu-Jin Jung; Subbiah Jeeva; Young-Man Kwon; Baik Lin Seong; Sang Moo Kang
Journal:  Antiviral Res       Date:  2019-05-28       Impact factor: 5.970

2.  RSV recombinant candidate vaccine G1F/M2 with CpG as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs.

Authors:  Na Li; Ling Zhang; Boyang Zheng; Wenjian Li; Jianxun Liu; Huixian Zhang; Ruihong Zeng
Journal:  Hum Vaccin Immunother       Date:  2019-04-29       Impact factor: 3.452

3.  A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.

Authors:  Youri Lee; Eun-Ju Ko; Ki-Hye Kim; Young-Tae Lee; Hye Suk Hwang; Young-Man Kwon; Barney S Graham; Sang Moo Kang
Journal:  Virology       Date:  2019-05-28       Impact factor: 3.616

4.  Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.

Authors:  Maurizio Chiriva-Internati; Yuefei Yu; Leonardo Mirandola; Marjorie R Jenkins; Caroline Chapman; Martin Cannon; Everardo Cobos; W Martin Kast
Journal:  PLoS One       Date:  2010-05-12       Impact factor: 3.240

5.  DNA immunization with plasmids encoding fusion and nucleocapsid proteins of bovine respiratory syncytial virus induces a strong cell-mediated immunity and protects calves against challenge.

Authors:  Mathieu Boxus; Marylène Tignon; Stefan Roels; Jean-François Toussaint; Karl Walravens; Marie-Ange Benoit; Philippe Coppe; Jean-Jacques Letesson; Carine Letellier; Pierre Kerkhofs
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

6.  Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies.

Authors:  John W Mapletoft; Laura Latimer; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

7.  TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.

Authors:  Teresa R Johnson; Srinivas Rao; Robert A Seder; Man Chen; Barney S Graham
Journal:  Vaccine       Date:  2009-04-03       Impact factor: 3.641

8.  Quantitative trait loci associated with the immune response to a bovine respiratory syncytial virus vaccine.

Authors:  Richard J Leach; Ronan G O'Neill; Julie L Fitzpatrick; John L Williams; Elizabeth J Glass
Journal:  PLoS One       Date:  2012-03-15       Impact factor: 3.240

9.  Intramuscular administration of a synthetic CpG-oligodeoxynucleotide modulates functional responses of neutrophils of neonatal foals.

Authors:  Noah D Cohen; Jessica R Bourquin; Angela I Bordin; Kyle R Kuskie; Courtney N Brake; Kaytee B Weaver; Mei Liu; M Julia B Felippe; Michael H Kogut
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

10.  Differential regulation of CCL-11/eotaxin-1 and CXCL-8/IL-8 by gram-positive and gram-negative bacteria in human airway smooth muscle cells.

Authors:  Razao Issa; Rosalinda Sorrentino; Maria B Sukkar; Shiranee Sriskandan; Kian Fan Chung; Jane A Mitchell
Journal:  Respir Res       Date:  2008-04-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.